Back to Results
First PageMeta Content
Chemistry / Chronic lower respiratory diseases / Respiratory physiology / Pulmonary function testing / Spirometry / Obstructive lung disease / Phenols / Indacaterol / Respimat / Pulmonology / Medicine / Respiratory therapy


OLODATEROL RESPIMAT Boehringer Ingelheim NDA[removed]FDA Advisory Committee Briefing Document December 19, 2012
Add to Reading List

Open Document

File Size: 1,66 MB

Share Result on Facebook

City

Ridgebury Rd Ridgefield / /

Company

Boehringer Ingelheim Pharmaceuticals Inc. / CI Cmax CMC CO / ABBREVIATIONS AND DEFINITIONS Abbreviation AC AE / BDI / /

Event

FDA Phase / /

IndustryTerm

manufacturing / /

MedicalCondition

Neoplasms / Lung Cancer / WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE / Administration-Related Bronchoconstriction / COPD / chronic obstructive pulmonary disease / MS / Asthma / /

Organization

American Thoracic Society / Ki LABA LAMA Definition Adjudication Committee / FDA / European Union / Food and Drug Administration / US Federal Reserve / /

Person

GINA GOLD HIPAA / /

Product

Baseline Dyspnea Index / Olodaterol Bronchodilator / U12-3926 / COPD / /

ProvinceOrState

Connecticut / /

Technology

Pharmacokinetics / /

SocialTag